EMA fast-tracks antidote to Pradaxa

Monday, September 28, 2015

The EMA has recommended granting a marketing authorization, following Accelerated Assessment, for Praxbind (idarucizumab) as a specific antidote to the anticoagulant medicine Pradaxa (dabigatran etexilate), when rapid reversal of its effect is required. Praxbind is to be used when a patient taking Pradaxa needs to undergo an emergency surgery or when life-threatening or uncontrolled bleeding occurs.

[Read More]

Venn Life Sciences to acquire Kinesis

Friday, September 25, 2015

Venn Life Sciences, a European CRO, has entered into an agreement to acquire the entire issued share capital of Kinesis Pharma, a Netherlands-based provider of specialist consultancy services around the chemical-pharmaceutical, nonclinical and early clinical development of drug products, for a total maximum consideration of up to $7.3 million (€6.5 million).

[Read More]

Report: Cancer deaths hitting U.K. in wallet

Tuesday, September 15, 2015

A new report says the difference in cancer survival rates between England and rest of Europe has stood at about 10% for the past 20 years, and closing that divide would add about £117 million ($180 million) a year to the U.K. economy.

[Read More]